Further analysis showed the interaction of ZYX with PTOV1 (commonly overexpressed in prostate cancer [35]) and CBP proteins (RA receptor coactivator), resulting in attenuation of the cytotoxic effect of RA [9]. Here, PTOV1 is linked to prostate cancer.